Association of Helicobacter pylori with Parkinson’s Disease
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Purpose Parkinson’s disease (PD) is a major neurological disorder that requires lifelong treatment, and the combined presence of Helicobacter pylori (H. pylori) infection can increase the required anti-PD medications. We aim to investigate the effect of H. pylori infection in Indian PD patients. Methods We prospectively recruited 36 PD patients from December 2007 to January 2011. All patients underwent a detailed neurological evaluation and serological examination for H. pylori infection. Seropositive and seronegative patients were considered to be the cases and controls, respectively. All patients who were seropositive received triple therapy for 2 weeks. Outcome measures of the mean ‘off’ Unified Parkinson’s Disease Rating Scale (UPDRS)-III score, mean ‘on’ UPDRS-III score, mean onset time, mean ‘on’ duration, and mean daily ‘on’ time were measured at baseline and at a 3-week follow-up. Results H. pylori-IgG positivity was present in 18 (50%) PD patients. The prevalence of men (72.2% vs. 33.3%), mean duration of disease (13.8 vs. 12.5) and mean levodopa equivalent daily dose (824 mg vs. 707 mg) were significantly higher among H. pylori positive patients than in controls (p<0.0001). Controls had a significantly longer ‘on’ duration and daily ‘on’ time, and better ‘on’ UPDRS-III scores. Seropositive patients took a significantly longer time to turn ‘on’ after a levodopa challenge. At the 3-week follow-up, H. pylori eradication significantly improved the mean ‘on’ UPDRS-III score, onset time, ‘on’ duration, and daily ‘on’ time. Conclusions H. pylori infection was present in 50% of Indian PD patients. H. pylori seropositivity was associated with a poor response to levodopa and increased medication usage, while eradication therapy was associated with better patient outcomes.
Abstract
Background and Purpose Parkinson’s disease (PD) is a major neurological disorder that requires lifelong treatment, and the combined presence of Helicobacter pylori (H. pylori) infection can increase the required anti-PD medications. We aim to investigate the effect of H. pylori infection in Indian PD patients. Methods We prospectively recruited 36 PD patients from December 2007 to January 2011. All patients underwent a detailed neurological evaluation and serological examination for H. pylori infection. Seropositive and seronegative patients were considered to be the cases and controls, respectively. All patients who were seropositive received triple therapy for 2 weeks. Outcome measures of the mean ‘off’ Unified Parkinson’s Disease Rating Scale (UPDRS)-III score, mean ‘on’ UPDRS-III score, mean onset time, mean ‘on’ duration, and mean daily ‘on’ time were measured at baseline and at a 3-week follow-up. Results H. pylori-IgG positivity was present in 18 (50%) PD patients. The prevalence of men (72.2% vs. 33.3%), mean duration of disease (13.8 vs. 12.5) and mean levodopa equivalent daily dose (824 mg vs. 707 mg) were significantly higher among H. pylori positive patients than in controls (p<0.0001). Controls had a significantly longer ‘on’ duration and daily ‘on’ time, and better ‘on’ UPDRS-III scores. Seropositive patients took a significantly longer time to turn ‘on’ after a levodopa challenge. At the 3-week follow-up, H. pylori eradication significantly improved the mean ‘on’ UPDRS-III score, onset time, ‘on’ duration, and daily ‘on’ time. Conclusions H. pylori infection was present in 50% of Indian PD patients. H. pylori seropositivity was associated with a poor response to levodopa and increased medication usage, while eradication therapy was associated with better patient outcomes.
참고문헌 (31)
- Nielsen HH, "Treatment for Helicobacter pylori infection and risk of Parkinson’s disease in Denmark", Eur J Neurol, 19, pp.864~869 (2012)
- Gupta BM, "Parkinson’s disease in India: an analysis of publications output during 2002-2011", Int J Nutr Pharmacol Neurol Dis, 3, pp.254~262 (2013)
- Gourie-Devi M, "Epidemiology of neurological disorders in India: review of background, prevalence and incidence of epilepsy, stroke, Parkinson’s disease and tremors", Neurol India, 62, pp.588~598 (2014)
- Wu YH, "Risk of premotor symptoms in patients with newly diagnosed PD: a nationwide, population-based, case-control study in Taiwan", PLoS One, 10, pp.e0130282~ (2015)
- Nafisah W, "High prevalence of Helicobacter pylori infection in Malaysian Parkinson’s disease patients", J Parkinsonism Restless Legs Syndr, 3, pp.63~67 (2013)
- Goodwin CS, "Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen. nov. as Helicobacter pylori comb. nov. and Helicobacter mustelae comb. nov., respectively", Int J Syst Evol Microbiol, 39, pp.397~405 (1989)
- Johnson A, "Guts & glory H. pylori:cause of peptic ulcer", Eukaryon, 3, pp.67~74 (2007)
- Nisha KJ, "Periodontal disease and Helicobacter pylori infection: a community-based study using serology and rapid urease test", J Investig Clin Dent, 7, pp.37~45 (2016)
- Hughes AJ, "Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases", J Neurol Neurosurg Psychiatry, 55, pp.181~184 (1992)
- Aggarwal OP, "A new instrument (scale) for measuring the socioeconomic status of a family: preliminary study", Indian J Community Med, 30, pp.111~114 (2005)
- Goetz CG, "Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations", Mov Disord, 19, pp.1020~1028 (2004)
- Papapetropoulos SS, "Patient diaries as a clinical endpoint in Parkinson’s disease clinical trials", CNS Neurosci Ther, 18, pp.380~387 (2012)
- Dobbs RJ, "Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 1: eradication of Helicobacter in the cachexia of idiopathic parkinsonism", Helicobacter, 10, pp.267~275 (2005)
- Dobbs SM, "Differential effect of Helicobacter pylori eradication on timetrends in brady", hypokinesia and rigidity in idiopathic parkinsonism, 2010, pp.15, 279~294
- Pierantozzi M, "Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations", Neurology, 66, pp.1824~1829 (2006)
- 김동준, "Helicobacter pylori Infection and Peptic Ulcer Disease In Patients with Liver Cirrhosis", The Korean Journal of Internal Medicine, 23(1), pp.16~21 (2008), 대한내과학회
- Choudhuri G, "Epidemiology of Helicobacter pylori in India", Indian J Gastroenterol, 19(Suppl 1), pp.S3~S6 (2000)
- Blaecher C, "Significantly higher frequency of Helicobacter suis in patients with idiopathic parkinsonism than in control patients", Aliment Pharmacol Ther, 38, pp.1347~1353 (2013)
- Bu XL, "The association between infectious burden and Parkinson’s disease: a casecontrol study", Parkinsonism Relat Disord, 21, pp.877~881 (2015)
- Schulz JD, "Cycad toxins, Helicobacter pylori and parkinsonism: cholesterol glucosides as the common denomenator", Med Hypotheses, 66, pp.1222~1226 (2006)
- Soykan I, "Gastric myoelectrical activity in patients with Parkinson’s disease: evidence of a primary gastric abnormality", Dig Dis Sci, 44, pp.927~931 (1999)
- Freestone PP, "Microbial endocrinology: experimental design issues in the study of interkingdom signalling in infectious disease", Adv Appl Microbiol, 64, pp.75~105 (2008)
- Hashim H, "Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson’s disease", PLoS One, 9, pp.e112330~ (2014)
- Bjarnason IT, "Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 2: response of facets of clinical idiopathic parkinsonism to Helicobacter pylori eradication. A randomized, double-blind, placebocontrolled efficacy study", Helicobacter, 10, pp.276~287 (2005)
- Weller C, "Role of inflammation in gastrointestinal tract in aetiology and pathogenesis of idiopathic parkinsonism", FEMS Immunol Med Microbiol, 44, pp.129~135 (2005)
- Gupta A, "Infectious causation of Parkinsonism:a review", J Dent Med Sci, 3, pp.1~3 (2012)
- Arismendi-Morillo G, "Comparison of three methods based on endoscopic gastric biopsies for diagnosis of Helicobacter pylori active infection in a clinical setting", Arq Gastroenterol, 48, pp.190~194 (2011)
- Mégraud F, "Diagnostic of Helicobacter pylori infection", Helicobacter, 21(Suppl 1), pp.8~13 (2016)
- Vagarali MA, "Clinical significance of various diagnostic techniques and emerging antimicrobial resistance pattern of Helicobacter Pylori from gastric biopsy samples", Indian J Med Microbiol, 33, pp.560~564 (2015)
- Gehlot V, "Low prevalence of clarithromycin-resistant Helicobacter pylori isolates with A2143G point mutation in the 23S rRNA gene in North India", J Glob Antimicrob Resist, 6, pp.39~43 (2016)
- Goetz CG, "Placebo response in Parkinson’s disease: comparisons among 11 trials covering medical and surgical interventions", Mov Disord, 23, pp.690~699 (2008)